Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Leukemia Année : 2020

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

(1) , (2) , (3) , (4, 5) , (6) , (6) , (7) , (8)
1
2
3
4
5
6
7
8

Résumé

Recent therapeutic advances for mantle cell lymphoma (MCL) include inhibitors of Bruton’s tyrosine kinase (BTK), a critical component in the B-cell receptor signaling pathway [1, 2]. Remarkably, approximately two thirds of patients with relapsed/refractory (R/R) MCL treated with ibrutinib, the first-in-class BTK inhibitor, achieve a durable response [3–5]. However, ibrutinib treatment also commonly produces off-target adverse events (AEs) such as bleeding, atrial fibrillation, diarrhea, and infection.

Dates et versions

hal-03383683 , version 1 (18-10-2021)

Identifiants

Citer

Simon Rule, Guillaume Cartron, Christopher Fegan, Franck Morschhauser, Lingling Han, et al.. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia, 2020, 34 (5), pp.1458-1461. ⟨10.1038/s41375-019-0658-7⟩. ⟨hal-03383683⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More